Dr. Chris Lu, CEO and cofounder of Laekna Therapeutics, shares Laekna’s ambition to deliver cures and improve the quality of life of patients globally, captured by the word ‘Laekna’, which is Old Norse for ‘to cure, to heal’. He also outlines Laekna’s focus on disease biology, specifically the areas of oncology and hepatology, as well as their comprehensive portfolio strategy, bolstered by their strategic partnership with Novartis, which includes three promising in-licensed compounds.
Laekna is committed to remaining a highly professional team and we keep our promises. To date, whatever we promised, we have delivered.
